Keybank National Association Galectin Therapeutics Inc Transaction History

Keybank National Association

  • $25.5 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022
SELL
$1.19 - $1.74 $119,000 - $174,000
-100,000 Closed
0 $0
Q3 2021

Nov 08, 2021
BUY
$2.59 - $4.15 $259,000 - $415,000
100,000 New
100,000 $388,000

Others Institutions Holding GALT

# of Institutions
91
Shares Held
9.65M
Call Options Held
1.16M
Put Options Held
1.98M
View Full List

About GALECTIN THERAPEUTICS INC

GALT Quotes by TradingView
  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $61.8M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Keybank National Association Portfolio

Follow Keybank National Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email